In Brief: GDUFA inspections, FDA’s inspection workforce, device warning letters, 3D drug printers, CMC/GMP guidance agenda
This article was originally published in The Gold Sheet
Executive Summary
FDA discusses GDUFA II inspectional transparency issues with industry; FDA plans global workforce; device warning letter rate fell; why FDA needs a 3D drug printer; and CMC trumps GMP in FDA agenda.